Bromelain Treatment Decreases Secretion of Pro-inflammatory Cytokines and Chemokines by Colon Biopsies in Vitro

Overview

Journal Clin Immunol

Specialty Allergy & Immunology

Date 2007 Dec 28

PMID 18160345

Citations 37

Authors

Jane E Onken

Paula K Greer

Brian Calingaert

Laura P Hale

Affiliations

Soon will be listed here.

Abstract

Oral bromelain has been anecdotally reported to decrease inflammation in ulcerative colitis (UC). Proteolytically active bromelain is known to decrease expression of mRNAs encoding pro-inflammatory cytokines by human leukocytes in vitro. To assess the effect of bromelain on mucosal secretion of cytokines in inflammatory bowel disease (IBD), endoscopic colon biopsies from patients with UC, Crohn's disease (CD), and non-IBD controls were treated in vitro with bromelain or media, then cultured. Secretion of pro-inflammatory cytokines and chemokines was measured. Significant increases in granulocyte colony-stimulating factor (G-CSF), interferon (IFN)-gamma, interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF) were detected in the media from actively inflamed areas in UC and CD as compared with non-inflamed IBD tissue and non-IBD controls. In vitro bromelain treatment decreased secretion of G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-gamma, CCL4/macrophage inhibitory protein (MIP)-1beta, and TNF by inflamed tissue in IBD. Bromelain may be a novel therapy for IBD.

Citing Articles

Evaluation of the physical properties of bromelain-modified biodentine for direct pulp capping.

Agrawal P, Chandak M, Patel A, Bhopatkar J BMC Oral Health. 2024; 24(1):1053.

PMID: 39252058 PMC: 11385152. DOI: 10.1186/s12903-024-04863-w.

Exploring the Therapeutic Potential of Bromelain: Applications, Benefits, and Mechanisms.

Kansakar U, Trimarco V, Manzi M, Cervi E, Mone P, Santulli G Nutrients. 2024; 16(13).

PMID: 38999808 PMC: 11243481. DOI: 10.3390/nu16132060.

Current Uses of Bromelain in Children: A Narrative Review.

Locci C, Chicconi E, Antonucci R Children (Basel). 2024; 11(3).

PMID: 38539412 PMC: 10969483. DOI: 10.3390/children11030377.

Taming the SARS-CoV-2-mediated proinflammatory response with BromAc.

Ferreira G, Clarindo F, Lopes Ribeiro A, Gomes-de-Pontes L, Carvalho L, Martins-Filho O Front Immunol. 2024; 14:1308477.

PMID: 38193087 PMC: 10773902. DOI: 10.3389/fimmu.2023.1308477.

Bromelain and ficin proteolytic effects on gliadin cytotoxicity and expression of genes involved in cell-tight junctions in Caco-2 cells.

Sadat Mousavi Maleki M, Aghamirza Moghim Ali Abadi H, Vaziri B, Shabani A, Ghavami G, Madanchi H Amino Acids. 2023; 55(11):1601-1619.

PMID: 37803248 DOI: 10.1007/s00726-023-03333-x.

References

ONeil D, Steidler L . Cytokines, chemokines and growth factors in the pathogenesis and treatment of inflammatory bowel disease. Adv Exp Med Biol. 2003; 520:252-85. View

Lafont F, Tran van Nhieu G, Hanada K, Sansonetti P, van der Goot F . Initial steps of Shigella infection depend on the cholesterol/sphingolipid raft-mediated CD44-IpaB interaction. EMBO J. 2002; 21(17):4449-57. PMC: 126195. DOI: 10.1093/emboj/cdf457. View

Hale L, Haynes B . Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol. 1992; 149(12):3809-16. View

Sartor R . Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994; 106(2):533-9. DOI: 10.1016/0016-5085(94)90614-9. View

Russell R, Blake Jr D . Cell association and invasion of Caco-2 cells by Campylobacter jejuni. Infect Immun. 1994; 62(9):3773-9. PMC: 303030. DOI: 10.1128/iai.62.9.3773-3779.1994. View

Munzig E, Eckert K, Harrach T, Graf H, Maurer H . Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett. 1994; 351(2):215-8. DOI: 10.1016/0014-5793(94)00860-4. View

Masson M . [Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice]. Fortschr Med. 1995; 113(19):303-6. View

Mynott T, Luke R, Chandler D . Oral administration of protease inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestine. Gut. 1996; 38(1):28-32. PMC: 1382975. DOI: 10.1136/gut.38.1.28. View

Reimund J, Wittersheim C, Dumont S, Muller C, Baumann R, Poindron P . Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996; 16(3):144-50. DOI: 10.1007/BF01540912. View

10.

Gaciong Z, Paczek L, Bojakowski K, Socha K, Wisniewski M, Heidland A . Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Nephrol Dial Transplant. 1996; 11(6):987-9. View

11.

Ogino M, Majima M, Kawamura M, Hatanaka K, Saito M, Harada Y . Increased migration of neutrophils to granulocyte-colony stimulating factor in rat carrageenin-induced pleurisy: roles of complement, bradykinin, and inducible cyclooxygenase-2. Inflamm Res. 1996; 45(7):335-46. DOI: 10.1007/BF02252946. View

12.

Majima M, Nishiyama K, Iguchi Y, Yao K, Ogino M, Ohno T . Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inflamm Res. 1996; 45(8):416-23. DOI: 10.1007/BF02252938. View

13.

Reimund J, Wittersheim C, Dumont S, Muller C, KENNEY J, Baumann R . Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996; 39(5):684-9. PMC: 1383392. DOI: 10.1136/gut.39.5.684. View

14.

Kleef R, Delohery T, Bovbjerg D . Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5. Pathobiology. 1996; 64(6):339-46. DOI: 10.1159/000164070. View

15.

Majima M, Kawashima N, Hiroshi I, Katori M . Effects of an orally active non-peptide bradykinin B2 receptor antagonist, FR173657, on plasma exudation in rat carrageenin-induced pleurisy. Br J Pharmacol. 1997; 121(4):723-30. PMC: 1564748. DOI: 10.1038/sj.bjp.0701194. View

16.

Yang S, Eckmann L, Panja A, Kagnoff M . Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology. 1997; 113(4):1214-23. DOI: 10.1053/gast.1997.v113.pm9322516. View

17.

Ina K, Kusugami K, Hosokawa T, Imada A, Shimizu T, Yamaguchi T . Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease. J Gastroenterol Hepatol. 1999; 14(1):46-53. DOI: 10.1046/j.1440-1746.1999.01807.x. View

18.

Chandler D, Mynott T . Bromelain protects piglets from diarrhoea caused by oral challenge with K88 positive enterotoxigenic Escherichia coli. Gut. 1999; 43(2):196-202. PMC: 1727222. DOI: 10.1136/gut.43.2.196. View

19.

Targoni O, Tary-Lehmann M, Lehmann P . Prevention of murine EAE by oral hydrolytic enzyme treatment. J Autoimmun. 1999; 12(3):191-8. DOI: 10.1006/jaut.1999.0271. View

20.

Mynott T, Ladhams A, Scarmato P, Engwerda C . Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells. J Immunol. 1999; 163(5):2568-75. View